The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease

Respirology

Volumn 15, Issue 8, 2010, Pages 1226-1232

  Corte, Tamera J ^a   Gatzoulis, Michael A ^a   Parfitt, Lisa ^a   Harries, Carl ^a   Wells, Athol U ^a   Wort, S John ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

6 minute walk test; Brain natriruretic peptide; Interstitial lung disease; Pulmonary hypertension; Sildenafil

Indexed keywords

ANTICOAGULANT AGENT; BRAIN NATRIURETIC PEPTIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; SILDENAFIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; EPISTAXIS; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HEART RIGHT VENTRICLE PRESSURE; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

COHORT STUDIES; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PIPERAZINES; PURINES; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS; WALKING;

EID: 78349257814     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01860.x     Document Type: Article

References (63)

1. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-52.
2. Agarwal R, Gupta D, Verma JS, et al. Noninvasive estimation of clinically asymptomatic pulmonary hypertension in idiopathic pulmonary fibrosis. Indian J. Chest Dis. Allied Sci. 2005; 47: 267-71.
3. Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur. Respir. J. 2005; 25: 783-8.
4. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am. J. Respir. Crit. Care Med. 2003; 167: 735-40.
5. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131: 657-63.
6. Yang SJ, Hoffman C, Mulligan K, et al. Pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis when listed for lung transplantation and at lung transplantation [Abstract]. Proc. Am. Thorac. Soc. 2006; 3: A369.
7. Nathan SD, Ahmad S, Koch J, et al. Serial measures of pulmonary artery pressures in patients with idiopathic pulmonary fibrosis. Chest 2005; 128 (Suppl. 1): S168.
8. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 650-6.
9. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-9.
10. Corte TJ, Wort SJ, Gatzoulis MA, et al. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 2009; 64: 883-8.
11. Corte TJ, Wort SJ, Gatzoulis MA, et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur. Respir. J. 2010; doi: 10.1183/09031936.00173509.
12. Lederer DJ, Arcasoy SM, Barr RG, et al. Racial and ethnic disparities in idiopathic pulmonary fibrosis: a UNOS/OPTN database analysis. Am. J. Transplant. 2006; 6: 2436-42.
13. Zisman DA, Karlamangla AS, Ross DJ, et al. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007; 132: 773-9.
14. IPF Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med. 2010; 367: 620-8.
15. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.
16. Madden BP, Allenby M, Loke TK, et al. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul. Pharmacol. 2006; 44: 372-6.
17. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131: 897-9.
18. Kircher BJ, Himelman RB, Schiller NB,. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am. J. Cardiol. 1990; 66: 493-6.
19. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler- catheterization study in 127 patients. J. Am. Coll. Cardiol. 1985; 6: 750-6.
20. De Lemos JA, Gibson CM, Antman EM, et al. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: observations from the TIMI 14 Trial. Am. Heart J. 2001; 141: 592-8.
21. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol. 2004; 43: 635-41.
22. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111-17.
23. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: 424-8.
24. Rossi R, Nuzzo A, Lattanzi A, et al. Sildenafil improves endothelial function in patients with pulmonary hypertension. Pulm. Pharmacol. Ther. 2008; 21: 172-7.
25. Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. 2005; 172: 105-13.
26. Ladha F, Bonnet S, Eaton F, et al. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am. J. Respir. Crit. Care Med. 2005; 172: 750-6.
27. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116: 238-48.
28. De Visser YP, Walther FJ, Laghmani H, et al. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir. Res. 2009; 10: 30.
29. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005; 353: 2148-57.
30. Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am. Heart J. 2006; 151: 851 e1-5.
31. Kataoka M, Satoh T, Manabe T, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ. J. 2005; 69: 461-5.
32. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 2002; 136: 515-22.
33. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2004; 24: 1007-10.
34. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. 2005; 171: 1292-7.
35. Channick RN, Hoch RC, Newhart JW, et al. Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1994; 149: 811-14.
36. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann. Intern. Med. 2000; 132: 435-43.
37. Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J. Heart Lung Transplant. 2008; 27: 329-34.
38. McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009; 54: S97-107.
39. Peacock AJ, Naeije R, Galie N, et al. End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur. Respir. J. 2009; 34: 231-42.
40. Latsi PI, Du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 2003; 168: 531-7.
41. Corte TJ, Wort SJ, Wells AU,. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarcoidosis Vasc. Diffuse Lung Dis. 2009; 26: 7-19.
42. Charbeneau RP, Peters-Golden M,. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin. Sci. (Lond.) 2005; 108: 479-91.
43. Wright L, Tuder RM, Wang J, et al. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1998; 157: 219-29.
44. Richter A, Yeager ME, Zaiman A, et al. Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2004; 170: 1340-8.
45. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med. 1991; 114: 464-9.
46. Galiè N, Grigioni F, Bacchi-Reggiani L, et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. EurJ. Clin. Invest. 1996; 26: A273.
47. Mutsaers SE, Foster ML, Chambers RC, et al. Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am. J. Respir. Cell Mol. Biol. 1998; 18: 611-19.
48. Uguccioni M, Pulsatelli L, Grigolo B, et al. Endothelin-1 in idiopathic pulmonary fibrosis. J. Clin. Pathol. 1995; 48: 330-4.
49. Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341: 1550-4.
50. Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am. J. Respir. Cell Mol. Biol. 1997; 16: 187-93.
51. Trakada G, Spiropoulos K,. Arterial endothelin-1 in interstitial lung disease patients with pulmonary hypertension. Monaldi Arch. Chest Dis. 2001; 56: 379-83.
52. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2009; 54: S43-54.
53. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2009; 30: 2493-537.
54. Schroll S, Arzt M, Sebah D, et al. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan. Respir. Physiol. Neurobiol. 2009; 170: 32-6.
55. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 177: 75-81.
56. King TE Jr, Brown KK, Raghu G, et al. The BUILD-3 trial: a prospective, randomized, double-blind, placebo-controlled study of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2010; 181: A6836.
57. Gunther A, Enke B, Markart P, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur. Respir. J. 2007; 29: 713-19.
58. Foley RJ, Metersky ML,. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration 2008; 75: 211-14.
59. Sharma S, Kashour T, Philipp R,. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex. Heart Inst. J. 2005; 32: 405-10.
60. Pitsiou GG, Spyratos D, Kioumis I, et al. Sarcoidosis-associated pulmonary hypertension: a role for endothelin receptor antagonists? Ther. Adv. Respir. Dis. 2009; 3: 99-101.
61. Simonneau G,. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J. Am. Coll. Cardiol. 2004; 43: 1S-90S.
62. Behr J, Ryu JH,. Pulmonary hypertension in interstitial lung disease. Eur. Respir. J. 2008; 31: 1357-67.
63. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-82.